Literature DB >> 16370407

Treatment of irritable bowel syndrome.

Susan K Hadley1, Stephen M Gaarder.   

Abstract

Irritable bowel syndrome affects 10 to 15 percent of the U.S. population to some degree. This condition is defined as abdominal pain and discomfort with altered bowel habits in the absence of any other mechanical, inflammatory, or biochemical explanation for these symptoms. Irritable bowel syndrome is more likely to affect women than men and is most common in patients 30 to 50 years of age. Symptoms are improved equally by diets supplemented with fiber or hydrolyzed guar gum, but more patients prefer hydrolyzed guar gum. Antispasmodic agents may be used as needed, but anticholinergic and other side effects limit their use in some patients. Loperamide is an option for treatment of moderately severe diarrhea. Antidepressants have been shown to relieve pain and may be effective in low doses. Trials using alosetron showed a clinically significant, although modest, gain over placebo, but it is indicated only for women with severe diarrhea-predominant symptoms or for those in whom conventional treatment has failed. Tegaserod has an advantage over placebo in constipation-predominant irritable bowel syndrome; it is indicated for up to 12 weeks of treatment in women. However, postmarketing reports of severe diarrhea and ischemic colitis further limit its use. Herbal therapies such as peppermint oil also may be effective in the treatment of irritable bowel syndrome. Therapies should focus on specific gastrointestinal dysfunctions (e.g., constipation, diarrhea, pain), and medications only should be used when nonprescription remedies do not work or when symptoms are severe.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16370407

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  10 in total

Review 1.  Is gluten a cause of gastrointestinal symptoms in people without celiac disease?

Authors:  Jessica R Biesiekierski; Jane G Muir; Peter R Gibson
Journal:  Curr Allergy Asthma Rep       Date:  2013-12       Impact factor: 4.806

Review 2.  The 5-HT3 receptor as a therapeutic target.

Authors:  Andrew J Thompson; Sarah C R Lummis
Journal:  Expert Opin Ther Targets       Date:  2007-04       Impact factor: 6.902

3.  Rapid response to cognitive behavior therapy predicts treatment outcome in patients with irritable bowel syndrome.

Authors:  Jeffrey M Lackner; Gregory D Gudleski; Laurie Keefer; Susan S Krasner; Cathrine Powell; Leonard A Katz
Journal:  Clin Gastroenterol Hepatol       Date:  2010-02-17       Impact factor: 11.382

4.  Binding sites for bilobalide, diltiazem, ginkgolide, and picrotoxinin at the 5-HT3 receptor.

Authors:  A J Thompson; R K Duke; S C R Lummis
Journal:  Mol Pharmacol       Date:  2011-04-19       Impact factor: 4.436

5.  Development and evaluation of a pH-dependent sustained release tablet for irritable bowel syndrome.

Authors:  Shuang-Qing Zhang; Ziyaur Rahman; Sridhar Thumma; Michael A Repka; Guo-Hua Chen; San-Ming Li
Journal:  Drug Dev Ind Pharm       Date:  2009-01       Impact factor: 3.225

6.  The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome.

Authors:  Shahin Merat; Shadi Khalili; Pardise Mostajabi; Anahita Ghorbani; Reza Ansari; Reza Malekzadeh
Journal:  Dig Dis Sci       Date:  2009-06-09       Impact factor: 3.199

7.  A Randomised, Cross-Over, Placebo-Controlled Study of Aloe vera in Patients with Irritable Bowel Syndrome: Effects on Patient Quality of Life.

Authors:  H A Hutchings; K Wareham; J N Baxter; P Atherton; J G C Kingham; P Duane; L Thomas; M Thomas; C L Ch'ng; J G Williams
Journal:  ISRN Gastroenterol       Date:  2010-10-11

8.  Efficacy and Safety of a Novel Herbal Medicine in the Treatment of Irritable Bowel Syndrome: A Randomized Double-Blinded Clinical Trial.

Authors:  Ghasem Bordbar; Mohammad Bagher Miri; Mahmoud Omidi; Saeed Shoja; Malihe Akhavan
Journal:  Gastroenterol Res Pract       Date:  2020-05-27       Impact factor: 2.260

Review 9.  Effectiveness of Fiber Supplementation for Constipation, Weight Loss, and Supporting Gastrointestinal Function: A Narrative Review of Meta-Analyses.

Authors:  Marc P McRae
Journal:  J Chiropr Med       Date:  2020-08-29

10.  IBS Patients' Treatment Expectancy and Motivation Impacts Quality of the Therapeutic Alliance With Provider: Results of the IBS Outcome Study.

Authors:  Jeffrey M Lackner; Brian M Quigley; Christopher D Radziwon; Alison M Vargovich
Journal:  J Clin Gastroenterol       Date:  2021 May-Jun 01       Impact factor: 3.174

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.